Advising a Biopharmaceutical Company on a Major Expansion of their Therapeutic Portfolio
US Biopharma SME
Research & Development
Our Client, a multinational biopharmaceutical company, had a wide range of successful products. However, they recognized that gene therapeutics technology represented an important area of the biopharmaceutical market that they couldn’t effectively address. The Client wanted to quickly understand this unfamiliar competitive and technological terrain, and get actionable advice on the best direction for their own growth into this area. They contacted CamIn seeking guidance on their next steps.
experts assembled for the consulting team.
sub-areas covered within client's field of interest.
technologies identified and evaluated.
CamIn worked with the Client’s research and development department to understand their goals for this expansion. We then assembled a team of more than ten leading experts on gene therapeutics, including several renowned university professors with expertise in in vivo gene therapeutics. We performed a thorough investigation of the technology area for the Client, delineating the relevant sub-areas (e.g. therapeutic agents, gene delivery tools) where they should consider focusing their R&D work.
We also evaluated each of these sub-areas, and the state-of-the-art technologies used in each area, considering the strengths, benefits, and market potential of each technology. In addition, CamIn shortlisted most promising disease areas and therapeutic approaches and forecast pre-clinical and early-stage clinical development pathways to recommend the most optimal technology assets for the expansion of the Client’s portfolio.